Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
2020 Life Science Innovation Northwest - Company Presenters


COMPANY PRESENTERS

A-Alpha Bio

A-Alpha Bio

Seattle, WA

Website: https://www.aalphabio.com/

Presentation Title: Massively multiplexed and quantitative characterization of antibody-antigen and other protein-protein interactions

Presented by: David Younger, PhD, CEO and Co-Founder

Description: The AlphaSeq platform enables quantitative measurements of millions of protein-protein interactions (PPI) simultaneously by reprogramming yeast agglutination with a next generation sequencing readout. Antibody discovery and lead selection require careful analysis of affinity, epitope, specificity, and cross-reactivity - all requiring measurements of PPIs. Similarly, the discovery and characterization of small molecules that disrupt or enhance protein interactions, including targeted protein degraders, requires measurement of PPIs for evaluating function and specificity. Here we will introduce the AlphaSeq platform and describe specific applications for biologics and small molecule development.

Abacus Bioscience

Abacus Bioscience

Sammamish, WA

Website: https://abacusbioscience.com/

Presentation Title: Immunotherapeutics for Cancer and Chronic Diseases

Presented by: Edward A Clark, PhD, Founder and CEO

Description: ABACUS BIOSCIENCE utilizes a patented platform technology to develop novel therapeutics for cancer and viral diseases. The experienced team at Abacus is working to create a durable biotherapeutics for cancer and chronic viral infections by breaking immune tolerance to existing disease. Our drugs activate therapeutic responses through an innate immune receptor, CD180, which plays a central role in immune regulation, and are designed to address medical gaps in currently available immunotherapies.

AbSci

AbSci

Vancouver, WA

Website: https://www.absci.com/

Presentation Title: Accelerated Drug Development and Manufacturing

Presented by: Melissa Patterson, PhD, Director, Alliance Management

Description: AbSci’s next-generation biomanufacturing technology has combined with KBI’s high level of quality and pursuit of cGMP excellence. In this combined presentation, Thomas Jung and Melissa Patterson will discuss how the two companies are coming together to accelerate the Gene-to-GMP process, reducing the process by 6 months or more!

Adaptive Biotechnologies

Adaptive Biotechnologies

Seattle, WA

Website: https://www.adaptivebiotech.com/

Presentation Title: Adaptive Biotechnologies Addresses COVID-19

Presented by: Mary Pat Lancelotta, VP of Corporate Marketing & Communications

Description: Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Advanced Cellular Dynamics

Advanced Cellular Dynamics

Seattle, WA

Website: https://acdynamics.com/

Presentation Title: Mapping Functional Kinase Inhibitor Spaces

Presented by: David Schwarz, PhD, CEO

Description: A panel of sixty-five cell-based tyrosine kinase assays was profiled with a collection of forty-one commercially available small molecule kinase inhibitors (many clinically viable). The collective activities of each compound across the entire panel were compared and used to assemble a circular activity dendrogram that segregates kinases based on their reactivities to these inhibitors, rather than their primary amino acid similarity. The resulting KinoScope™ identifies eleven related families of kinases, within which we have nominated a single sentinel KinoCore™ member that incorporates and defines the molecular spaces available for a kinase inhibitor to occupy within a particular family. These reagents and tools simplify the process and reduce the economic burden underlying the exploration of off-target activities.

AGC Biologics

AGC Biologics

Bothell, WA

Website: https://www.agcbio.com/

Presented by: Patricio Massera

Allen Institute for Immunology

Allen Institute for Immunology

Seattle, WA

Website: https://alleninstitute.org/what-we-do/immunology/

Presentation Title: Integrated Multi-omic Profiling of the Human Immune System in Health and Disease

Presented by: Thomas F. Bumol, PhD, Executive Vice President, Director of Immunology

Description: The Allen Institute for Immunology was launched in December of 2018 to establish a research discovery engine based on an industrial scale, multi-omics profiling pipeline to better understand the complexities of the human immune system in health and disease. In full collaboration with several prominent academic collaborators, the institute combines state of the art single cell technologies in cytometry, transcriptomics and epigenetics with plasma protein profiling and human meta data in longitudinal studies of both normal humans and patients with cancer, autoimmunity and SARS-CoV-2 infection. The Institute’s goals are deliberately translational, and we continue to seek partnerships that will advance our research to clinical utility and positive impact for patients.

Altasciences

Altasciences

Everett, WA

Website: https://www.altasciences.com/

Presentation Title: Altasciences, A Different Kind of CRO

Presented by: Mike Broadhurst, General Manager

Description: Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. Our video provides more information.

AltPep

AltPep

Seattle, WA

Website: https://www.AltPep.com

Presented by: Valerie Daggett, Founder and CEO

Aptevo Therapeutics

Aptevo Therapeutics

Seattle, WA

Website: https://aptevotherapeutics.com/

Presented by: Jane Gross PhD, SVP R&D and CSO

Astellas Pharma (Universal Cells)

Astellas Pharma (Universal Cells)

Seattle, WA Site; Tokyo, Japan Headquarters

Website: http://www.universalcells.com/

Presentation Title: Cell Therapy Immune Oncology at Astellas

Presented by: Gregory Block PhD, Director of Business Development

Description: Astellas acquired Seattle-based Universal Cells in 2018 and is leveraging the platform to become a leader in cell therapy immune oncology.

AVM Biotechnology

AVM Biotechnology

Seattle, WA

Website: https://avmbiotech.com/

Presentation Title: Global Pandemics Demand Global Solutions

Presented by: Theresa Deisher, PhD, Founder and CEO

Description: AVM Biotechnology was founded in 2008 by Dr. Theresa Deisher, Ph.D. With over 30 years of successful pharmaceutical research experience and holding over 47 patents, Dr. Deisher leads a team of scientists dedicated to changing what a diagnosis of cancer, autoimmunity, or chronic infectious disease means to patients and their loved ones. AVM received FDA IND approval to test our lead product AVM0703 for treatment of lymphoid malignancies. The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19. To further that research, AVM Biotechnology has filed with the FDA for approval to proceed with clinical trials against this virus as well as Influenza virus which also causes deadly ARDS. With a global advisory team including experts in oncology, respiratory disease, and vaccines, AVM is well-poised to bring AVM0703 to market. We have raised $15 million from family and friends thus far and are seeking an additional $24 million as well as government and industry partners.

Bristol Myers Squibb

Bristol Myers Squibb

Bothell, WA Site; New York, NY Headquarters

Website: https://www.bms.com/

Presented by: Mark J. Bachleda, PharmD, MBA, Vice President US Commercial, Cell Therapy

CuraCloud

CuraCloud

Seattle, WA

Website: https://curacloud.net/

Presentation Title: Collaborative Medical Image AI R&D

Presented by: Edmund Butler, VP Corporate Development

Description: Deep Learning is transforming medical image diagnostics. Learn how CuraCloud’s Seattle AI lab collaborates with device manufacturers and medical group practices to create unique solutions and achieve regulatory clearances.

Curevo Vaccine Inc

Curevo Vaccine Inc

Seattle, WA

Website: https://curevovaccine.com/

Presentation Title: Next Generation adjuvanted sub-unit Zoster Vaccine

Presented by: George Simeon, CEO

Description: Curevo Vaccine is a US-based, clinical stage biotech company dedicated to bringing next generation vaccines to the market - quickly and efficiently. We will present clinical data from our completed Phase I study, which assessed safety and immunogenicity in a healthy population of 90 subjects aged 18 to <50. We will also discuss our objectives for future clinical research.

Cyrus Biotechnology

Cyrus Biotechnology

Seattle, WA

Website: https://cyrusbio.com/

Presentation Title: Cyrus Biotechnology Recent Progress

Presented by: Lucas Nivon, CEO

Description: Cyrus Biotechnology works in partnership with large Pharma and Biotech firms in biologics discovery and optimization using computational tools. More recently we have started internal programs in biobetters with a special focus in rare disease with academic collaborators such as the Broad Institute in CRISPR. We will describe our core software platform and scientific highlights.

Genemod

Genemod

Seattle, WA

Website: https://genemod.net/

Presented by: Jacob Lee, CEO & Co-Founder

HDT Bio

HDT Bio

Seattle, WA

Website: https://www.hdt.bio/

Presentation Title: The Promise, Potential, and Practicality of RNA Vaccines

Presented by: Steven Reed, PhD, CEO

Description: Using our experience in adjuvant and formulation sciences we have developed a third generation RNA platform cable of inducing strong and durable immune responses with a single injection. This technology, capable of enabling rapid, effective, and large scale responses to emerging pathogens, is currently being developed for clinical application.

Healionics Corporation

Healionics Corporation

Seattle, WA

Website: https://healionics.com/

Presentation Title: Novel synthetic blood vessel

Presented by: Mike Connolly, CEO

Description: Healionics is a clinical stage company addressing the critical need for improved means of dialysis access in patients with kidney failure. Our STARgraft vascular graft (artificial blood vessel) resists the problems of occlusion and infection suffered by current devices. We also have an exciting product pipeline based on our platform STAR® biomaterial, which has a unique ability to prevent both scarring and infection in a wide variety of other implantable device applications.

HealthTech Connex

HealthTech Connex

Surrey, BC

Website: https://healthtechconnex.com/

Presentation Title: Disrupting brain potential

Presented by: Dr. Ryan D'Arcy, PhD, EngL, President & CSO

Description: Using innovative technologies to change brain potential. To learn more watch Dr. D’Arcy present at a recent TEDx conference .

IntuitiveX

IntuitiveX

Seattle, WA

Website: https://www.intuitive-x.com/

Presentation Title: Successfully Navigating the Life Science IP Space

Presented by: Mark Han Esq & Simon Robinson, President & Chief Legal Officer; Chief IP Officer

Description: Interested in how you can turn your IP into a competitive advantage? The life sciences intellectual property space is notoriously difficult to navigate. However, with our expertise, we've been able to co-create new IP, issue IP in record time, and successfully sell and acquire IP. Want to gain insider information into how to better strategize, defend, and commercialize your IP assets. Look no further!

Just-Evotec Biologics

Just-Evotec Biologics

Seattle, WA

Website: http://www.justbiotherapeutics.com/

Presentation Title: Flexible, Efficient Biomanufacturing by Design

Presented by: Mike Vandiver, Senior Vice President, Biotherapeutic Operations

Description: Project Access: How Just - Evotec Biologics is increasing biologics manufacturing capacity with the construction of its new facility in Redmond, Washington.

KBI Biopharma

KBI Biopharma

Durham, NC

Website: https://www.kbibiopharma.com/

Presentation Title: Accelerated Gene-to-GMP Process

Presented by: Thomas Jung, MS, VP Business Development

Description: AbSci’s next-generation biomanufacturing technology has combined with KBI’s high level of quality and pursuit of cGMP excellence. In this combined presentation, Thomas Jung and Melissa Patterson will discuss how the two companies are coming together to accelerate the Gene-to-GMP process, reducing the process by 6 months or more!

Lightspeed Microscopy

Lightspeed Microscopy

Seattle, WA

Website: https://www.lightspeedbio.com/

Presentation Title: Lightspeed Microscopy: Next Generation Pathology

Presented by: Nicholas Reder, CEO

Description: Lightspeed is transforming the analog, 2D, slide-based world of pathology to digital, 3D, and slide-free. Our proprietary sample prep, patented open-top light-sheet microscope, and advanced 3D visualization / analysis tools enable new insights into complex biological tissues. We are seeking customers and strategic partners to join us in bringing 3D pathology to pre-clinical R&D.

Link Immunotherapeutics, Inc.

Link Immunotherapeutics, Inc.

Seattle, WA

Website: https://www.linkimmunotherapeutics.com/

Presentation Title: Putting Teeth into BiTEs

Presented by: Christopher Mehlin, PhD, Senior Staff Scientist, Fred Hutch

Description: Link Immunotherapeutics is developing best-in-class bispecific antibodies for the treatment of cancer. We are particularly interested in bispecific antibodies that exhibit synergy when employed together as a way to tackle both tumor heterogeneity and T cell exhaustion. This is technology that was developed at and licensed from the Fred Hutchinson Cancer Research Center.

MarqMetrix

MarqMetrix

Seattle, WA

Website: https://www.marqmetrix.com/

Presentation Title: Providing Greater Control of Biopharmaceutical Manufacturing

Presented by: Marc Malone, VP Business Operations & Strategy

Description: Biopharmaceutical manufacturing is a complex process where the slightest variations can have dramatic consequences. I will explain how the MarqMetrix All-In-One spectrometer can help achieve greater control of the manufacturing process by providing continuous measurements of key variables in real time. The data from the measurements can automatically be sent to a control system allowing for adjustments that will reduce cycle times, increase yields and improve quality.

MedIntelliBase

MedIntelliBase

Redmond, WA

Website: https://medintellibase.com/

Presentation Title: MedIntelliBase®: expert content curation

Presented by: Victoria Hunsicker Sanko, MBA, President & CEO

Description: MedIntelliBase is expert at medical information and content curation, and communication of that information to medical industry professionals and those where personal medical intelligence is in demand. This is not search. not aggregation. It’s expert medical content curation. MedIntelliBase is seeking a tech-savvy partner to codevelop and market its cloud and mobile systems as licensable software for personal use by the more than 1 million medical industry professionals around the globe.

NanoSurface Biomedical

NanoSurface Biomedical

Seattle, WA

Website: https://www.nanosurfacebio.com/

Presentation Title: Elliot will present NanoSurface Bio’s mission to engineer predictive stem cell-derived tissues to accelerate the development of new medicines.

Presented by: Elliot Fisher, Chief Business Officer

Description: NanoSurface technologies are particularly effective in increasing the predictivity and maturity of human stem cell-derived heart tissues. By incorporating more predictive human heart tissue models earlier in the preclinical drug development process, drug developers are able to more accurately eliminate preliminary therapeutics that are likely to fail in the more costly clinical trials, saving valuable time and resources, and enhance their ability to discover safer and more effective therapies.

Neoleukin Therapeutics

Neoleukin Therapeutics

Seattle, WA

Website: https://www.neoleukin.com/

Presented by: Umut Ulge, MD, PhD, VP, Clinical Development

Novuson Surgical, Inc.

Novuson Surgical, Inc.

Bothell, WA

Website: https://www.novuson.com

Presentation Title: Novuson Introduces Disruptive Electrosurgical Platform: The UltraStat

Presented by: Stuart Mitchell, CEO

Description: Novuson Is an innovative medical device company, founded 2014 based in Bothell, WA, developing the world's first Direct Therapeutic Ultrasound (DTU) surgical instrument platform for minimally invasive, robotic and endoscopic surgeries. Novuson’s launch product (3mm Mini LS) is essential for Vessel Sealing/Dividing in Gynecological, Urological, Bariatric, Pediatric, Trauma, and other surgical specialties. The first product launch of the platform will be first-in-class 3mm Mini-Laparoscopic Sealer/Divider. Use of Novuson systems will significantly reduce bleeding, substantially improve patient outcomes and reduce hospital costs.

OncoResponse

OncoResponse

Seattle, WA

Website: http://www.oncoresponseinc.com/

Presentation Title: OncoResponse Immuno-Oncology Corporate Overview

Presented by: Kamal Puri, PhD, CSO

Description: In a broad strategic alliance with MD Anderson Cancer Center OncoResponse uses a proprietary B-cell technology platform to mine the immune system of cancer patients who have responded to cancer immunotherapy to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies to treat cancer. OncoResponse has several antibodies directed at modulating immunosuppression of the tumor microenvironment in pre-clinical development. OR2805, a lead antibody repolarizes immunosuppressive macrophages to become pro-inflammatory and assist in tumor killing, and is bound for clnicial studies in 2021.

OncoSenX

OncoSenX

Seattle, WA

Website: https://www.oncosenx.com/

Presented by: Dr. Henry Garcia, Chief Scientist

Opticyte

Opticyte

Seattle, WA

Website: http://www.opticyte.com/

Presentation Title: Introducing CellSat™, an Oxygen Deficiency Device

Presented by: Lorilee S. L. Arakaki, PhD, CEO

Description: Opticyte is a medical device company developing the only product to reduce organ failure by early identification and monitoring of oxygen deficiency to organs. Oxygen deficiency to organs (shock) results in organ failure, a devastating condition and a major expense to hospitals. Opticyte’s disposable sensor has a $1B SAM in US and EU.

OtoNexus Medical Technologies

OtoNexus Medical Technologies

Seattle, WA

Website: https://otonexus.com/

Presentation Title: The Gap in the Diagnosis and Treatment of Middle Ear Infections

Presented by: Caitlin Cameron, Chair and CEO

Description: At OtoNexus, our mission is to significantly decrease the use of unnecessary antibiotic prescriptions in the treatment of middle ear infections. Middle ear infections are the #1 reason for prescribing antibiotics, #1 reason for surgery, and the 2nd most common reason that children visit an emergency department. It is troubling that current diagnostic tools for middle ear infections are only accurate 50% of the time. As a result, the CDC estimates that antibiotics are prescribed in 85% of cases, but only appropriate in just 15-20% of cases. OtoNexus has developed the world’s first technology that can characterize middle ear infections in less than 2 seconds. Before now, that information could only be obtained with surgery. At last, physicians have a tool that provides the data they need to determine the smart use of antibiotics. Access to this information will lead to improved patient outcomes, better and faster treatment, reduced antibiotic usage, and significantly reduced healthcare costs. We are seeking go to market funding. With your help, we can finally address the considerable gap between the diagnosis and treatment of middle ear infections. By joining us, you can give physicians the tools they need to tackle a ubiquitous disruptive problem for children.

Photon Biosciences, LLC

Photon Biosciences, LLC

Spokane, WA

Website: https://photonbiosciences.com/

Presented by: Chandima Bandara, CEO

Presage Biosciences

Presage Biosciences

Seattle, WA

Website: https://presagebio.com/

Presentation Title: Pioneering Innovative Translational Oncology Solutions

Presented by: Richard Klinghoffer, PhD, CEO

Description: The success rate for cancer drug candidates entering clinical trials is a dismal 8%. An underlying cause is that new drugs are evaluated in laboratory models that do not accurately reflect the complexity of patient tumors and do not reliably predict patient benefit in the clinic. The Presage CIVO platform addresses this problem by uniquely enabling the simultaneous evaluation and comparison of multiple drugs, drug candidates, and drug combinations directly in a patient’s tumor, without the toxicities associated with typical clinical drug exposures. Presage has established clinical feasibility, a dedicated engineering and clinical operations team, a clear regulatory path, and a network of trained clinical sites to execute CIVO-enabled Phase 0 trials. Through innovative collaborations, Presage has established strong relationships with major cancer drug development companies and it’s turnkey Phase 0 business is revenue generating with full profitability in 2021.

Prevencio, Inc.

Prevencio, Inc.

Kirkland, WA

Website: https://www.prevenciomed.com/

Presentation Title: AI-driven Diagnostics for Cardiac and Kawasaki Disease

Presented by: Rhonda Rhyne, President & CEO

Description: Prevencio is a commercial-stage medical diagnostics company harnessing the power of AI to improve the accuracy of cardiovascular diagnostic & prognostic tests. Using our proprietary AI-driven platform, we have developed seven multi-protein, algorithmically-scored HART tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores. We have 18 peer-reviewed manuscripts and presentations. Partnerships include Seattle Children’s Hospital (for a custom diagnostic for Kawasaki Disease) and Microsoft as well as a letter of intent with Bayer.

Primary Peptides

Primary Peptides

Vancouver, BC

Website: https://www.primarypeptides.com/

Presentation Title: Developing novel peptide therapeutics using platform technologies

Presented by: Max S. Cynader, PhD, CEO

Description: Primary Peptides Inc is a clinical-stage biotech company based in Vancouver, Canada. We are developing novel peptide therapeutics using two platform technologies: 1) peptide array for identifying, targeting, and disrupting specific protein-protein interactions; 2) peptide-mediated protein knockdown technology that can replace antisense and siRNA technology platforms in many indications with greater specificity and greater temporal precision. We have signed 4 pharma partnerships so far. We are looking for pharma partners and also high quality investors that bring more than money.

RareCyte, Inc

RareCyte, Inc

Seattle, WA

Website: https://rarecyte.com/

Presentation Title: Whole slide 20-plex imaging

Presented by: Joe Victor, President & CEO

Description: Learn about a new spatial biology imaging platform that enables scientists to deeply characterize tissue samples, in up to 20 channels, using a novel single-pass, whole-slide imaging technology. Applications in immuno-oncology will be presented.

Sana Biotechnology

Sana Biotechnology

Seattle, WA

Website: https://sana.com/

Presentation Title: Sana Biotechnology Company Overview

Presented by: Nate Hardy, CFO

Description: Discussion regarding Sana Biotechnology’s focus on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy.

Seattle Genetics

Seattle Genetics

Bothell, WA

Website: https://www.seattlegenetics.com/

Presentation Title: Seattle Genetics, Transformative Therapies Targeting Cancer

Presented by: Nancy Whiting, PharmD, Executive VP, Development

Description: At Seattle Genetics revolutionary science meets transformative cancer therapy. With multiple successfully developed and FDA-approved therapies, Seattle Genetics is the region’s leading biotechnology company. ADCETRIS® (brentuximab vedotin) and PADCEV™ (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA™ (tucatinib) is a small molecule tyrosine kinase inhibitor and is approved for certain HER2-positive metastatic breast cancers. The company has a pipeline of novel targeted therapies at various stages of preclinical and clinical testing, as well as continuing development of our approved medicines. We also are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.

SEngine Precision Medicine

SEngine Precision Medicine

Seattle, WA

Website: https://senginemedicine.com/

Presentation Title: Personalizing Cancer Treatment Beyond Genomics

Presented by: Carla Grandori, MD PhD, CEO

Description: SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform. Discover more at SEngineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

SiDx, Inc.

SiDx, Inc.

Seattle, WA

Website: https://sidx.com/

Presentation Title: SiDx: Rapid Diagnostics

Presented by: Eric Larsen, CEO

Description: SiDx is modernizing blood testing via Silicon Photonics. SiDx believes that test results should be available during the doctor’s visit, not hours or days later. SiDx is enabling rapid, panel based diagnostics at the point of care.

SunFly Brands

SunFly Brands

Seattle, WA

Website: https://sunflybrands.com/

Presentation Title: The SunFly SPF Indicator Stamp

Presented by: Michael Croix, CEO

Description: SunFly has raised $1.5MM and is currently in joint-development and licensing discussions with 2 of the 3 largest global sunscreen brands for our technologies. 15 domestic and international patents have been filed in 3 patent classes to protect and maintain global market share. SunFly’s team includes leading experts in the science of chromophores, ink formulation and new product development and commercialization including the former VP of Research for Global Skin and Suncare Innovation at Johnson & Johnson, the lead photochromic scientist that developed Transitions Lens technology and senior operating executives of several Fortune 500 CPG companies. Working prototypes are in development and SunFly will conduct usability testing this summer to demonstrate the SunFly SPF Indicator Stamp can increase sunscreen usage and decrease sunburn rates with sunscreen users. A $2.4MM SBIR grant will be applied for through NCI/NIH in early September with a funding decision expected by late November. If SunFly is not awarded the SBIR grant, we may seek a bridge round to help finalize development and translate our technologies onto our licensee's branded products.

Tasso Inc

Tasso Inc

Seattle, WA

Website: https://www.tassoinc.com/

Presentation Title: Clinical-grade, at-home, self-sampling blood collection

Presented by: Ben Casavant, PhD, Co-founder, CEO

Description: Tasso is an emerging healthcare company that is transforming the traditional blood collection process with a more convenient and virtually painless approach that focuses on the patient. The Tasso OnDemand devices enable people to collect their own blood without any training, all from the comfort and privacy of their home. These fast and easy-to-use products are being adopted by leading academic medical institutions, government agencies, comprehensive cancer centers, and pharmaceutical organizations around the world for a wide variety of applications, including routine diagnostics, chronic disease monitoring, infectious disease surveillance, athletic and sports testing, virtual clinical trials, global health, and healthcare for under-served populations. Tasso recently completed an oversubscribed $17 million Series A financing round that was led by Hambrecht Ducera Growth Ventures and included participation from Foresite Capital, Merck Global Health Innovation Fund, Vertical Venture Partners, Techstars, and Cedars-Sinai. The company is using the proceeds to scale manufacturing and operations to meet the growing demand for its line of innovative Tasso OnDemand devices. To date, Tasso has now raised a total of $38.6 million from grants, private investments, and co-development collaborations.

TwinStrand BioSciences, Inc.

TwinStrand BioSciences, Inc.

Seattle, WA

Website: https://twinstrandbio.com/

Presentation Title: Ultrasensitive Genetic Detection: Below One-In-One-Million

Presented by: Jesse J. Salk MD, PhD, CEO & Founder

Description: TwinStrand is a science-first genomics company based around Duplex Sequencing, an ultra-sensitive DNA analysis technology designed to improve cancer diagnostics. We use a combination of specialized biochemistry and powerful cloud-based computation to improve the accuracy of existing DNA sequencers by more than 10,000-fold. This unprecedented resolution lets us solve a variety of clinically actionable oncologic ‘needle in a haystack’ problems such as early detection of cancer, monitoring for residual tumor cells after therapy and identification of new chemicals and environmental exposures that put people at risk for cancer. We make it possible for researchers to see faint signals that were previously hidden, to help our collective effort to reduce global burden of cancer.

University of Washington

University of Washington

Seattle, WA

Website: https://www.washington.edu/

Presentation Title: UW Responds to COVID-19

Presented by: Rad Roberts, PhD, Director, Corporate Relations

Description: UW researchers continue to work with corporate, civic, and academic partners to turn promising ideas into solid science, applications, and products that improve human health. UW and its partners are playing a leading role in fighting Covid-19. So far, the Institute for Health Metrics and Evaluation built one of the most cited pandemic models, Virology developed testing and scaled it up, Computer Science Engineering built a powerful contact tracing system, Immunology is testing new therapeutic candidates in their BSL3 facility, the Institute for Protein Design is developing on a vaccine, and Medicine is treating patients. All of this work is done with our partners. We look forward to working with you

 
Membership Management Software Powered by YourMembership  ::  Legal